Egrifta's 2 mg daily regimen was calibrated against an averaged HIV-associated lipodystrophy trial population. It was not set for your baseline IGF-1, your mannitol or other excipient sensitivities, your tolerance for injection-site reactions, the cadence your pituitary actually responds on, or the supply windows when manufactured Egrifta SV or Egrifta WR is short. The labeled dose interruption rule (IGF-1 above two standard deviations of the age- and sex-adjusted normal) only matters if the strength on the vial can be matched to where your IGF-1 actually sits.
That fit work is what a 503A compounding pharmacy can legally do for tesamorelin, on a narrow lane. The molecule is the same 44-amino-acid GHRH analog the FDA reviewed. With a prescriber's documented clinical rationale, the preparation can be lyophilized at a strength the manufactured Egrifta-family products do not offer, formulated without an excipient the patient reacts to, or dispensed to bridge a documented manufactured-product supply interruption. What RonanRx will not do is compound tesamorelin for anti-aging, general body composition in adults without HIV, athletic performance, or as a microgram-dose cocktail with other GHRH or GHRP peptides. Those uses sit outside the labeled indication and outside FDA's essentially-a-copy guidance.
This is the older arrangement: a doctor writes for a named patient, a licensed pharmacist prepares it, and the dispensing record is auditable. Modern oversight is what keeps that arrangement honest.
In brief
Tesamorelin Explained
Tesamorelin is a once-daily (or, in the newer Egrifta WR formulation, once-weekly) subcutaneous injection that stimulates the body's own growth hormone 2628. The FDA approved it in November 2010 as Egrifta for adults with HIV who have built up excess abdominal fat as a complication of antiretroviral therapy, a condition called HIV-associated lipodystrophy. A reformulated daily product (Egrifta SV) was approved in 2019, and a once-weekly version (Egrifta WR) was approved in 2024.
It works by mimicking a brain hormone called GHRH, which tells the pituitary gland to release pulses of growth hormone 1. Across two large phase 3 trials in HIV-associated lipodystrophy, tesamorelin reduced visceral abdominal fat by roughly 15-18% over 26 weeks 3. It is the only FDA-approved medicine for that specific condition. Outside HIV-associated lipodystrophy, tesamorelin is not FDA-approved for any indication, including weight loss, anti-aging, or general body composition.
At a glance
Quick Facts About Tesamorelin
Category
Synthetic growth hormone-releasing hormone (GHRH) analog
Active ingredient
Tesamorelin acetate, a 44-amino-acid analog of human GHRH (1-44) bearing an N-terminal trans-3-hexenoyl modification that confers resistance to dipeptidyl peptidase-IV (DPP-IV) degradation
FDA-approved branded forms
Egrifta (approved November 10, 2010), Egrifta SV (2019 reformulation with 4-week stability post-reconstitution), and Egrifta WR (2024 once-weekly subcutaneous reformulation), all indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
Route
Subcutaneous injection, daily for Egrifta and Egrifta SV; once weekly for Egrifta WR
Evidence posture
Two phase 3 trials in HIV-associated abdominal lipodystrophy [falutz2007, falutz2010_jaids] established efficacy of the manufactured product, with parallel evidence for liver fat reduction in HIV-associated NAFLD [stanley2014, stanley2019]
FDA-approval status
Manufactured Egrifta, Egrifta SV, and Egrifta WR are FDA-approved for HIV-associated abdominal lipodystrophy only. Compounded tesamorelin is not FDA-approved and is not approved for any non-HIV indication.
Compounded under
503A, patient-specific prescription only, and only when the manufactured Egrifta/Egrifta SV/Egrifta WR product cannot meet a documented clinical need
Important compounding caution
Compounded tesamorelin for HIV-associated lipodystrophy is essentially a copy of an FDA-approved product unless the prescriber documents a patient-specific reason the manufactured product cannot be used (excipient sensitivity, dose individualization, route or strength not commercially available). Compounded tesamorelin for anti-aging, body composition in adults without HIV, or other off-label indications is outside the FDA-approved labeling and not supported by the published efficacy program.
Prescription review
Patient-Specific Prescription Only
Tesamorelin on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is Tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH, residues 1-44). The molecule carries an N-terminal trans-3-hexenoyl modification that protects against cleavage by dipeptidyl peptidase-IV (DPP-IV), the principal degradation pathway for endogenous GHRH. This modification extends the plasma half-life sufficiently to permit once-daily subcutaneous administration of the original Egrifta and Egrifta SV products, and once-weekly administration of Egrifta WR 26.
Tesamorelin was developed by Theratechnologies under the development name TH9507 and licensed for U.S 26. commercialization to EMD Serono. The FDA approved Egrifta on November 10, 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A reformulated daily product (Egrifta SV) was approved in 2019 and offers a longer in-use beyond-use date after reconstitution, simplifying patient handling. A once-weekly subcutaneous reformulation (Egrifta WR) was approved by the FDA in 2024 for the same indication.
The drug substance in all three approved products is tesamorelin acetate. Reconstituted product is administered by subcutaneous injection in the abdomen, with site rotation. Tesamorelin is supplied as a lyophilized powder for reconstitution with sterile water for injection (Egrifta SV) or with the manufacturer-supplied diluent (Egrifta WR), per labeling 272826.
How it works
How Tesamorelin Works
Class
GHRH analog (peptide)
First studied
FDA-approved 2010
Common forms
Subcutaneous injection
Compounding category
503A, patient-specific prescription
Tesamorelin binds and activates the GHRH receptor on pituitary somatotropes, stimulating pulsatile endogenous release of growth hormone (GH). The downstream rise in serum insulin-like growth factor-1 (IGF-1) mediates many of the peripheral metabolic effects, including lipolysis in visceral adipose tissue. Because tesamorelin acts through the patient's own pituitary, the resulting GH secretion preserves the physiologic pulsatile pattern, which is mechanistically distinct from continuous exposure produced by direct administration of recombinant human GH 56.
The N-terminal trans-3-hexenoyl modification confers resistance to DPP-IV proteolysis, the principal degradation route for endogenous GHRH (1-44). This molecular protection extends the plasma half-life of tesamorelin to approximately 26-38 minutes, sufficient to generate a discrete and sustained GH secretory response after each subcutaneous dose. With repeated daily dosing, IGF-1 levels rise to a new steady state typically within 2 weeks and decline back toward baseline within weeks of discontinuation.
Net clinical effects in adults with HIV-associated lipodystrophy include preferential reduction of visceral adipose tissue, smaller reductions in trunk subcutaneous fat, modest changes in lipid profile, and an expected dose-dependent rise in IGF-1 13. Effects on liver fat are well characterized in HIV-associated NAFLD 1319.
Research history
Tesamorelin Research History
Tesamorelin (TH9507) was developed by the Canadian biotechnology company Theratechnologies during the 2000s as a stable analog of human GHRH (1-44) intended to restore physiologic pulsatile GH secretion in clinical contexts where the axis is suppressed. Phase 2 evaluation in HIV-associated lipodystrophy demonstrated reductions in visceral adipose tissue and supported pivotal phase 3 development. The first pivotal trial 1 published in the New England Journal of Medicine in December 2007 randomized 412 HIV-infected adults with abdominal fat accumulation to tesamorelin 2 mg subcutaneously daily versus placebo for 26 weeks; visceral adipose tissue by CT decreased 15.2% with tesamorelin versus 5.0% increase on placebo, with parallel reductions in trunk fat and triglycerides and an expected rise in IGF-1 26.
An extension phase reported by Falutz and colleagues 2 in AIDS in 2008 characterized long-term safety and efficacy in patients continuing tesamorelin through 52 weeks. The second pivotal phase 3 trial 3, published in the Journal of Acquired Immune Deficiency Syndromes in 2010, randomized 404 HIV-infected adults to tesamorelin or placebo for 26 weeks with a 26-week safety extension; visceral adipose tissue decreased approximately 18% on tesamorelin versus a modest increase on placebo, with improvements in trunk-to-limb fat ratio and waist circumference. A companion publication 4 reported the IGF-1 dynamics and metabolic profile across the development program. Pooled analyses 9 integrated phase 3 data to characterize the predictors of visceral fat response and the relationship between reduced visceral adiposity and metabolic outcomes including triglycerides, adiponectin, and inflammatory markers 7. On November 10, 2010, FDA approved Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy 26.
Subsequent clinical development extended tesamorelin into HIV-associated nonalcoholic fatty liver disease. Stanley and colleagues (2014, JAMA) reported that tesamorelin reduced hepatic fat content by proton magnetic resonance spectroscopy in HIV-infected adults with abdominal adiposity and hepatic steatosis over six months 13. The phase 3 Lancet HIV trial published by Stanley and colleagues in 2019 19 randomized 61 adults with HIV-associated NAFLD to tesamorelin or placebo for 12 months, demonstrating absolute reduction in hepatic fat fraction (-4.1% on tesamorelin versus +0.9% on placebo at 12 months) and a lower rate of fibrosis progression 26. Translational work characterized tesamorelin-responsive hepatic transcriptomic signatures 20, targeted proteomic and transcriptomic responder pathways and reductions in circulating markers of immune activation 22, reductions in FGF21 paralleling liver fat reduction 17, and effects on muscle composition 18. The Lake and colleagues 2021 analysis 21 documented improvements in fat quality independent of fat quantity changes.
Cognitive aging studies have evaluated GHRH-analog stimulation in older adults with mild cognitive impairment. The Baker and colleagues 2012 trial 10 in Archives of Neurology randomized 152 older adults (87 with mild cognitive impairment and 65 cognitively intact) to 20 weeks of daily subcutaneous tesamorelin or placebo and reported improvements in executive function, with the Friedman and colleagues 2013 substudy 11 using magnetic resonance spectroscopy to document GABA, N-acetylaspartate, and myo-inositol changes consistent with neuroprotection. These trials are mechanistic and do not establish tesamorelin as a treatment for cognitive disorders. Russo and colleagues 2024 24 characterized tesamorelin efficacy and safety in HIV-infected adults on integrase inhibitors, and Ellis and colleagues 2025 25 reported effects on neurocognitive performance in adults with HIV and abdominal obesity. Reformulation activity produced Egrifta SV (FDA-approved 2019 with improved post-reconstitution stability) and Egrifta WR (FDA-approved 2024 as a once-weekly subcutaneous product) 272826.
Timeline
Tesamorelin Timeline
2007Falutz et al 1. publish phase 3 pivotal trial of tesamorelin in HIV-associated lipodystrophy (N=412, 26 weeks) in NEJM, VAT reduced 15.2% vs +5.0% on placebo
2008Falutz et al 2. report long-term (52-week) safety and efficacy extension in AIDS
2010Second pivotal phase 3 trial (Falutz et al., JAIDS, N=404) plus safety extension confirms 18% VAT reduction at 26 weeks 3
2010Companion phase 3 publication (Falutz et al., JCEM) characterizes IGF-1 dynamics and metabolic profile 4
2010FDA approves Egrifta (tesamorelin) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (November 10, 2010) 26
2011Stanley et al 5. (JCEM) characterize tesamorelin effect on endogenous GH pulsatility and insulin sensitivity in healthy men
2011Makimura et al 6. (Growth Horm IGF Res), relationship of adiponectin to endogenous GH pulse parameters with GHRH-analog stimulation
2011Stanley et al 7. (AIDS), tesamorelin effects on inflammatory markers and relationship to visceral adipose reduction
2011Dhillon (Drugs) review of tesamorelin for HIV-associated lipodystrophy 8
2012Stanley et al 9. (Clin Infect Dis), pooled phase 3 analysis: visceral adiposity reduction associated with improved metabolic profile
2012Baker et al 10. (Arch Neurol), controlled trial of daily tesamorelin in mild cognitive impairment and healthy older adults; improvements in executive function over 20 weeks
2013Friedman et al 11. (JAMA Neurol), GHRH-analog effects on brain GABA, N-acetylaspartate, and myo-inositol by magnetic resonance spectroscopy in MCI and healthy aging
2014Stanley et al 13. (JAMA), tesamorelin reduces hepatic fat content by proton MR spectroscopy in HIV-associated NAFLD over 6 months
2017Clemmons et al 15. (PLoS One), phase 2 safety and metabolic effects of tesamorelin in adults with type 2 diabetes (12 months)
2017Braun et al 17. (Growth Horm IGF Res), FGF21 decreases after liver fat reduction with tesamorelin
2017Adrian et al 16. (AIDS), visceral fat reduction with tesamorelin associated with improved liver enzymes in HIV
2019Stanley et al 19. (Lancet HIV), phase 3 trial of tesamorelin in HIV-associated NAFLD over 12 months: significant reduction in hepatic fat and lower rate of fibrosis progression
2019Fourman et al 18. (J Frailty Aging), tesamorelin decreases muscle fat and increases muscle area in adults with HIV
2020Fourman et al 20. (JCI Insight), hepatic transcriptomic signatures responsive to tesamorelin in HIV-associated NAFLD
2021Lake et al 21. (AIDS), tesamorelin improves fat quality independent of fat quantity changes
2021Stanley et al 22. (Clin Infect Dis), GHRH reduces circulating markers of immune activation in parallel with hepatic immune-pathway effects in HIV-associated NAFLD
2022Fourman and Grinspoon (JCEM) review approach to the patient with lipodystrophy including tesamorelin pharmacology 23
2024Russo et al 24. (AIDS), tesamorelin efficacy and safety in HIV-infected adults on integrase inhibitor regimens
2025Ellis et al 25. (J Infect Dis), effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity
Natural role
Biological Role of Tesamorelin
Growth hormone-releasing hormone is the master positive regulator of the somatotrope axis. Hypothalamic GHRH secretion drives pulsatile pituitary GH release, which in turn stimulates hepatic and tissue IGF-1 production. The axis mediates linear growth in childhood, body composition regulation across the lifespan (increases in lean mass, reductions in visceral adiposity, modulation of insulin sensitivity and lipid handling), and tissue-specific effects on bone, skeletal muscle, and immune function.
In HIV-associated lipodystrophy, the somatotrope axis is dysregulated: many adults exhibit reduced GH pulse amplitude and reduced 24-hour integrated GH secretion in the context of excess visceral adiposity, which itself feeds back to suppress GH secretion via free fatty acid and hyperinsulinemia-mediated mechanisms. Tesamorelin restores pulsatile GH secretion at the level of the pituitary somatotrope, distinct from direct exogenous administration of recombinant GH; the rationale for tesamorelin in HIV-associated lipodystrophy is therefore physiologic restoration of a suppressed endogenous axis 1412.
Clinical contexts studied
Clinical Contexts for Tesamorelin
HIV-associated lipodystrophy with excess abdominal fat in adults fda approved
FDA-approved indication for Egrifta, Egrifta SV, and Egrifta WR. This is the only FDA-approved indication for tesamorelin.
Two pivotal phase 3 randomized double-blind placebo-controlled trials 13 in HIV-infected adults with abdominal fat accumulation demonstrated approximately 15-18% reduction in visceral adipose tissue by CT at 26 weeks on tesamorelin 2 mg subcutaneously daily versus minimal change on placebo. The long-term extension data 2 supported continued efficacy through 52 weeks with discontinuation associated with regain of visceral fat. Pooled analyses 9 characterized the relationship between visceral fat reduction and metabolic profile (triglycerides, adiponectin, inflammatory markers 7). Egrifta SV (2019 reformulation) and Egrifta WR (2024, once-weekly) carry the same labeled indication 262728.
HIV-associated nonalcoholic fatty liver disease well studied
Studied in two randomized controlled trials; not an FDA-approved indication.
Stanley et al. (2014, JAMA) 13 randomized 50 adults with HIV, abdominal fat accumulation, and hepatic steatosis to tesamorelin 2 mg daily versus placebo for 6 months; hepatic fat content by proton magnetic resonance spectroscopy decreased relatively by approximately one-third. The phase 3 Lancet HIV trial 19 randomized 61 adults with HIV-associated NAFLD to 12 months of tesamorelin versus placebo, demonstrating absolute reduction in hepatic fat fraction and a lower rate of fibrosis progression. Translational analyses characterized tesamorelin-responsive hepatic transcriptomic signatures 20, reductions in circulating immune-activation markers 22, and reductions in FGF21 paralleling hepatic fat reduction 17.
Cognitive function in mild cognitive impairment and healthy older adults well studied
Studied in a single controlled trial with imaging substudy; mechanistic only and does not establish tesamorelin as a treatment for cognitive disorders.
Baker and colleagues (2012, Arch Neurol) 10 randomized 152 older adults (87 with amnestic mild cognitive impairment, 65 cognitively intact) to 20 weeks of subcutaneous tesamorelin 1 mg daily or placebo and reported improvements in executive function on tesamorelin in both groups. The companion magnetic resonance spectroscopy substudy 11 documented increases in brain GABA and changes in N-acetylaspartate and myo-inositol consistent with neuroprotective signaling. Neither trial supports tesamorelin as an approved treatment for cognitive impairment, and the FDA has not approved tesamorelin for any cognitive indication.
Body composition in HIV-infected adults on integrase inhibitor regimens well studied
Post-marketing population-specific evaluation; consistent with the FDA-approved labeling.
Russo and colleagues (2024, AIDS) 24 reported efficacy and safety of tesamorelin in HIV-infected adults on contemporary integrase strand transfer inhibitor regimens, the dominant antiretroviral class in current practice. Findings support continued relevance of tesamorelin in the current treatment era. Fourman and colleagues (2019, J Frailty Aging) 18 reported decreased intramuscular adipose tissue and increased muscle cross-sectional area on tesamorelin.
Neurocognitive performance in adults with HIV and abdominal obesity well studied
Studied in a randomized trial; tesamorelin is not FDA-approved for cognitive endpoints.
Ellis and colleagues (2025, J Infect Dis) 25 reported effects of tesamorelin on neurocognitive performance in adults with HIV and abdominal obesity. The result extends the body composition rationale to a neurocognitive substudy population but does not establish a cognitive indication; tesamorelin is not FDA-approved for cognitive function in any population.
Off-label use
Off-Label Uses of Tesamorelin
Visceral adiposity reduction in adults with type 2 diabetes (without HIV) well studied
Studied in a single phase 2 trial; not an FDA-approved indication.
Clemmons and colleagues (2017, PLoS One) 15 randomized adults with type 2 diabetes to tesamorelin or placebo for 12 months and reported reductions in visceral adipose tissue and triglycerides without clinically meaningful changes in HbA1c or fasting glucose. The trial demonstrated tolerability but did not lead to an expansion of the FDA-approved indication beyond HIV-associated lipodystrophy.
Body composition and anti-aging in adults without HIV emerging
Not an FDA-approved indication. The published evidence base for tesamorelin is confined to HIV-associated lipodystrophy, HIV-associated NAFLD, type 2 diabetes (phase 2), and cognitive substudies in older adults; routine use for body composition or anti-aging in adults without HIV is outside the published trial populations.
Outside the FDA-approved labeling, anecdotal use of tesamorelin for body composition or anti-aging in adults without HIV has been promoted in the consumer market. The published efficacy program does not establish benefit in this population, and the FDA has not approved tesamorelin for any non-HIV indication 29. RonanRx does not compound tesamorelin for body composition or anti-aging indications 28.
FDA-approved use
FDA-Approved Uses of Tesamorelin
Brand
Indication
Year
Route
Egrifta
Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
2010
Subcutaneous injection, once daily
Egrifta SV
Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (reformulated daily product with improved post-reconstitution stability)
2019
Subcutaneous injection, once daily
Egrifta WR
Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (once-weekly reformulation)
2024
Subcutaneous injection, once weekly
The FDA-approved manufactured products are Egrifta (approved November 10, 2010 for HIV-associated abdominal lipodystrophy), Egrifta SV (2019 reformulated daily product with a four-week beyond-use date after reconstitution under refrigeration), and Egrifta WR (2024 once-weekly subcutaneous formulation). All three products share the same labeled indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The drug substance is tesamorelin acetate in each product; the products differ in formulation, reconstitution procedure, and dosing frequency 26.
Labeled limitations of use state that the long-term cardiovascular safety of tesamorelin has not been established, that tesamorelin is not indicated for weight loss, and that the effect of tesamorelin on disease progression of HIV-associated lipodystrophy is not known 262728. Discontinuation is associated with re-accumulation of visceral fat; long-term continuation must be weighed against safety considerations including IGF-1 elevation and glucose intolerance signal.
Compounded use
Compounded Tesamorelin (503A)
Tesamorelin is FDA-approved as Egrifta, Egrifta SV, and Egrifta WR for one indication only: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy 2728. Compounded tesamorelin under 503A is highly restricted in this regulatory landscape. FDA's guidance on compounded drug products that are essentially copies of approved drug products 29 limits compounding of a drug that is commercially available except when the prescriber documents a patient-specific clinical need that the manufactured product cannot meet. Acceptable reasons typically fall into three categories: (1) documented sensitivity to a component of the manufactured Egrifta SV or Egrifta WR formulation; (2) a strength or concentration not commercially available that is medically necessary; or (3) a documented supply interruption of the manufactured product.
RonanRx compounds tesamorelin only on a patient-specific prescription with documented clinical rationale meeting one of these categories for an adult with HIV-associated lipodystrophy or a comparable medical need that the manufactured Egrifta-family products cannot accommodate. Compounded tesamorelin is not dispensed for anti-aging, general body composition in adults without HIV, athletic performance, or other off-label indications. These uses sit outside the FDA-approved labeling and outside the published efficacy program for tesamorelin; compounding pharmacies that dispense tesamorelin for these indications operate outside the framework of section 503A as interpreted by FDA's essentially-a-copy guidance 30.
Compounded tesamorelin preparations are typically dispensed as lyophilized powder for reconstitution prior to subcutaneous injection. The compounded preparation is not bioequivalent to Egrifta, Egrifta SV, or Egrifta WR; clinicians and patients should understand that PK/PD characteristics of a compounded preparation may differ from published manufactured-product data, particularly when excipients, lyophilization conditions, or container closure differ from the reference product. The published phase 3 efficacy evidence for tesamorelin 1319 was generated with the manufactured product and does not transfer to compounded preparations without separate stability, potency, and tolerability evaluation 27.
Formulations and routes
Tesamorelin Formulations and Routes
Form
Concentration
Description
Sterile lyophilized powder for subcutaneous injection (compounded)
Custom, typically reconstituted to deliver 1-2 mg per daily subcutaneous dose on a patient-specific prescription
Sterile lyophilized preparation compounded under USP General Chapter <797> on a patient-specific prescription. Container closure, excipient profile, and lyophilization conditions are documented per batch and matched to the patient's clinical profile. Beyond-use dating follows USP <797> requirements and pharmacy stability data.31
Manufactured Egrifta SV
1 mg per delivered dose after reconstitution (2 mg daily total typically administered as two 1 mg injections, per labeling)
FDA-approved 2019 reformulated daily product supplied as lyophilized powder for reconstitution with sterile water for injection. Reconstituted product is stable for up to four weeks under refrigeration, simplifying patient handling compared with the original Egrifta product.27
Manufactured Egrifta WR
Once-weekly subcutaneous dose per current FDA labeling
FDA-approved 2024 once-weekly subcutaneous reformulation supplied as lyophilized powder reconstituted with the manufacturer-supplied diluent. Reduces injection burden from daily to weekly administration for the labeled indication.28
Routes used in published literature: subcutaneous.
Dosing
Tesamorelin Dosing
Route
Population
Range
Duration
Study type
Subcutaneous
Adults with HIV-associated lipodystrophy (Egrifta and Egrifta SV labeled regimen)
2 mg subcutaneously once daily, injected into the abdomen with site rotation
Continued use balanced against IGF-1 elevation and tolerability; discontinuation is associated with re-accumulation of visceral fat
Doctor-prescribed only. The FDA-approved daily regimen for Egrifta and Egrifta SV is 2 mg subcutaneously once daily into the abdomen with site rotation. The 2024 Egrifta WR product is administered subcutaneously once weekly per its label 26. Treatment effect on visceral fat is observable by approximately 13 weeks and reaches a plateau over the 26-week pivotal trial period; continued dosing is required to maintain effect, with discontinuation associated with re-accumulation of visceral fat 13.
IGF-1 must be monitored at baseline and periodically on therapy. Per labeling, IGF-1 levels exceeding two standard deviations above the age- and sex-adjusted normal range should prompt dose interruption or discontinuation given the theoretical concern for IGF-1-mediated adverse outcomes including potential effects on neoplasia. Compounded tesamorelin should mirror the manufactured-product regimen unless the prescriber documents a patient-specific reason for variance 2728.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Tesamorelin Safety
Safety overview
Tesamorelin safety is characterized primarily by injection-site reactions, arthralgia, peripheral edema, paresthesia, hypoesthesia, myalgia, and an expected dose-dependent rise in IGF-1 13226. Across the pivotal phase 3 trials and the safety extensions, injection-site reactions were the most common adverse event, occurring in approximately 25% of tesamorelin-treated participants versus a lower rate on placebo; most were mild and did not lead to discontinuation. Arthralgia and peripheral edema were the most common non-injection-site adverse events at incidence above placebo. Hypersensitivity reactions including rash, urticaria, and rare anaphylaxis have been reported in post-marketing surveillance.
The IGF-1 elevation is a class-relevant labeling consideration. Tesamorelin produces a sustained rise in serum IGF-1 reflecting endogenous GH secretion; labeling recommends IGF-1 monitoring at baseline and periodically with dose interruption if IGF-1 exceeds two standard deviations above the age- and sex-adjusted normal range. Glucose intolerance is a labeled concern: across the phase 3 program, small increases in fasting glucose and 2-hour glucose on oral glucose tolerance testing were observed in some participants, with rare progression to diabetes 13. Tesamorelin should not be used in patients with active malignancy, and known or suspected pituitary tumor or other CNS tumor is a contraindication 26.
Long-term cardiovascular safety has not been established. The labeled population is HIV-infected adults with lipodystrophy, a population with elevated baseline cardiovascular risk in whom the contribution of tesamorelin per se cannot be separated from background risk. Effects on liver enzymes are typically favorable in HIV-associated NAFLD populations 161319. Effects on body composition include decreased intramuscular adipose tissue and increased muscle cross-sectional area 18 and improvements in fat quality independent of fat quantity 21. Pharmacovigilance literature relevant to compounded peptide therapy generally cautions against compounded preparations dispensed outside documented patient-specific clinical need; the published clinical evidence for tesamorelin is generated with manufactured product and does not transfer to compounded preparations without separate stability and potency data 262728.
Contraindications
Tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma, populations in whom endogenous somatotrope function may be insufficient to support a meaningful response. Tesamorelin is contraindicated in patients with active malignancy (either newly diagnosed or recurrent), in patients with known hypersensitivity to tesamorelin or to mannitol (an excipient in the manufactured product), and in pregnancy.
Caution applies in patients with diabetes mellitus, glucose intolerance, or risk factors for diabetes given the labeled glucose intolerance signal; in patients with a history of pancreatitis; and in patients receiving concomitant therapies known to affect glucose metabolism. Tesamorelin should be discontinued in patients who develop signs or symptoms of pituitary or other neoplasia during therapy 262728.
Drug interactions
Tesamorelin is a peptide cleared by proteolytic catabolism and is not metabolized by cytochrome P450 enzymes; clinically significant CYP-mediated drug-drug interactions are not expected. Glucocorticoid replacement requirements may need adjustment in patients receiving concomitant glucocorticoids, given GH-axis interactions with the hypothalamic-pituitary-adrenal axis. The labeled glucose intolerance signal warrants attention in patients receiving insulin or oral hypoglycemic agents, where small changes in glycemic control may require dose adjustment of antidiabetic therapy.
Cytochrome P450 substrates with a narrow therapeutic index may warrant monitoring after tesamorelin initiation in theory, as GH-axis activation can modestly modulate hepatic CYP expression; clinically meaningful interactions of this kind have not been characterized in the published trial program. Concomitant use with corticosteroids may decrease therapeutic response to tesamorelin 262728.
Adverse events
Across the pivotal phase 3 program 132, the most common adverse events with tesamorelin versus placebo were injection-site reactions (erythema, pruritus, pain, irritation, hematoma, urticaria, rash at site), arthralgia, peripheral edema, paresthesia, hypoesthesia, myalgia, nausea, vomiting, fatigue, headache, and dyspepsia. Injection-site reactions were typically mild to moderate, concentrated in the early weeks of therapy, and infrequently caused discontinuation. Hypersensitivity reactions occurring as systemic urticaria, pruritus, flushing, and rare anaphylaxis have been reported in post-marketing surveillance.
IGF-1 elevation is an expected pharmacodynamic effect and not an adverse event per se; clinically relevant elevations above the age- and sex-adjusted reference range prompted dose interruption per protocol. Small increases in fasting plasma glucose, fasting insulin, and HbA1c were observed in some participants; rare progression to overt diabetes occurred, and glucose intolerance is a labeled concern across all three approved products 262728. Anti-tesamorelin antibodies were detected in approximately 50% of patients by 26 weeks; antibody formation did not consistently predict loss of efficacy in pooled analyses but contributed to between-patient variability in IGF-1 response and visceral fat reduction. Liver enzyme effects were typically favorable in HIV-associated NAFLD populations 1613.
Monitoring
Monitoring Tesamorelin Therapy
Baseline assessment should include a focused history for hypothalamic-pituitary axis disruption, current or prior malignancy, pituitary tumor, diabetes mellitus or glucose intolerance, pancreatitis, hypersensitivity, and pregnancy status. Baseline laboratory should include IGF-1, fasting plasma glucose and HbA1c, and routine metabolic panel. The labeled population in HIV-associated lipodystrophy will additionally have antiretroviral therapy history, viral load, CD4 count, and lipid panel documented.
On therapy: IGF-1 at baseline and periodically with dose interruption if levels exceed two standard deviations above the age- and sex-adjusted normal range; fasting plasma glucose and HbA1c at intervals appropriate to the patient's risk; assessment of injection-site tolerance at clinic visits; reassessment of indication-specific response (visceral adipose tissue or trunk fat circumference) at approximately 26 weeks and thereafter at clinically appropriate intervals. Patients should be educated to recognize and report symptoms of hypersensitivity, pancreatitis, hyperglycemia, and any new neurologic or visual symptoms that might suggest pituitary pathology 262728.
Special populations
Tesamorelin in Special Populations
Pregnancy
Tesamorelin is contraindicated in pregnancy. Animal reproduction studies showed adverse developmental effects at clinically relevant exposures, and tesamorelin is not indicated for any condition for which the benefit would justify use in pregnancy 262728. Pregnancy status should be confirmed before initiation in patients with reproductive potential.
Lactation
There are no data on the presence of tesamorelin in human milk, its effects on the breastfed infant, or its effects on milk production. The labeled approach is shared decision-making weighing the developmental and health benefits of breastfeeding alongside the patient's clinical need for tesamorelin 262728.
Pediatric
Safety and effectiveness in pediatric patients have not been established. Tesamorelin is not labeled for pediatric use 262728. The published clinical evidence is in adult populations only.
Geriatric
Limited data exist for tesamorelin in adults aged 65 and older. The Baker (2012) trial in mild cognitive impairment and healthy older adults included participants aged 55-87 and demonstrated executive function effects without a distinct age-related safety signal 10. The HIV-associated lipodystrophy pivotal program enrolled predominantly middle-aged adults; the labeled population now includes older adults with HIV. Endogenous GH and IGF-1 decline with age, so absolute IGF-1 response to tesamorelin may be modulated by baseline somatotrope function 262728.
Renal impairment
Dedicated renal-impairment pharmacokinetic studies are limited. Tesamorelin is a peptide cleared by proteolytic catabolism; the renal contribution to clearance is minor 262728. Dose adjustment on the basis of renal function is not specified in current labeling; clinical judgment applies in patients with severe renal impairment given limited dedicated data.
Hepatic impairment
Dedicated hepatic-impairment pharmacokinetic studies are limited. Cytochrome P450 metabolism is not a significant clearance pathway. Dose adjustment on the basis of hepatic function is not specified in current labeling. In the published HIV-associated NAFLD trials 1319, tesamorelin was administered to adults with mild to moderate hepatic steatosis with acceptable safety; severe hepatic impairment has not been studied 262728.
Evidence quality
Tesamorelin Evidence Quality
Evidence supporting the FDA-approved Egrifta, Egrifta SV, and Egrifta WR products for HIV-associated abdominal lipodystrophy is robust within its narrow indication 29. Two pivotal phase 3 randomized double-blind placebo-controlled trials 13 totaling more than 800 adults demonstrated approximately 15-18% reduction in visceral adipose tissue by CT at 26 weeks, with a long-term extension publication characterizing safety and durability through 52 weeks 2 and a companion publication characterizing IGF-1 and metabolic profile 4. Pooled analyses 9 characterized predictors of response and the relationship between visceral fat reduction and metabolic outcomes (triglycerides, adiponectin, inflammatory markers 7). Mechanistic and pharmacology studies in healthy adults 56 characterized the pulsatile GH response.
Evidence in HIV-associated NAFLD is also strong, with two randomized trials 1319 demonstrating significant reductions in hepatic fat by proton magnetic resonance spectroscopy and a lower rate of fibrosis progression at 12 months in the phase 3 Lancet HIV trial 29. Translational evidence 202217 characterizes tesamorelin-responsive hepatic transcriptomic and circulating inflammatory and metabolic signatures. Cognitive aging studies 1011 provide mechanistic evidence for GHRH-analog effects on executive function and brain neurochemistry but do not establish a cognitive indication. Phase 2 evaluation in type 2 diabetes 15 demonstrated tolerability and visceral adipose tissue reduction without a clinically meaningful glycemic worsening signal.
Evidence specifically supporting compounded tesamorelin preparations is absent, there is no parallel efficacy program for compounded tesamorelin. Compounded use under 503A is justified only by patient-specific clinical factors that the manufactured Egrifta, Egrifta SV, or Egrifta WR product cannot accommodate 29. The published phase 3 evidence base was generated with manufactured product and does not transfer to compounded preparations without separate stability, potency, and tolerability evaluation. Use for indications outside HIV-associated lipodystrophy (body composition, anti-aging, athletic performance) is outside the FDA-approved labeling and outside the published efficacy program.
Phase 3 randomized, double-blind, placebo-controlled trial of tesamorelin 2 mg subcutaneously daily versus placebo in HIV-infected adults with abdominal fat accumulation
412
26 weeks
Visceral adipose tissue by CT decreased 15.2% with tesamorelin versus a 5.0% increase on placebo; reductions in trunk fat, waist circumference, and triglycerides with expected rise in IGF-1 1
52-week extension of the pivotal phase 3 trial characterizing long-term safety and durability of effect
—
52 weeks
Continued visceral fat reduction in patients maintained on tesamorelin; regain of visceral fat in patients switched to placebo, supporting the requirement for continued therapy to maintain effect 2
Phase 3 randomized, double-blind, placebo-controlled trial of tesamorelin 2 mg daily versus placebo in HIV-infected adults with abdominal fat accumulation, with 26-week safety extension
404
26 weeks primary + 26-week extension
Visceral adipose tissue decreased approximately 18% on tesamorelin versus a small increase on placebo; improvements in trunk-to-limb fat ratio and waist circumference, with favorable lipid changes and an acceptable safety profile 3
Randomized, placebo-controlled mechanistic trial in healthy older men with overnight frequent venous sampling and FSIVGTT for insulin sensitivity
—
Acute and 2-week dosing
Tesamorelin restored pulsatile GH secretion to a pattern resembling younger adults and improved insulin sensitivity; established the mechanistic distinction from continuous exogenous GH 5
Pooled analysis across the phase 3 development program in HIV-associated lipodystrophy
—
—
Reduction in visceral adiposity associated with improved metabolic profile including triglycerides and adiponectin in HIV-infected patients receiving tesamorelin 9
Phase 2 randomized, double-blind, placebo-controlled trial of tesamorelin 1 mg subcutaneously daily versus placebo in older adults with amnestic mild cognitive impairment (n=87) and cognitively intact older adults (n=65)
152
20 weeks
Improvements in executive function on tesamorelin in both MCI and cognitively intact older adults; mechanistic only, does not establish tesamorelin as a treatment for cognitive disorders 10
Magnetic resonance spectroscopy substudy of the Baker (2012) trial measuring brain GABA, N-acetylaspartate, and myo-inositol in MCI and healthy older adults
—
—
Increases in brain GABA and changes in N-acetylaspartate and myo-inositol consistent with neuroprotective effects of GHRH-analog stimulation; mechanistic and does not establish a cognitive indication 11
Randomized, double-blind, placebo-controlled trial of tesamorelin 2 mg subcutaneously daily versus placebo in HIV-infected adults with abdominal fat accumulation and hepatic steatosis; proton magnetic resonance spectroscopy for hepatic fat
50
6 months
Hepatic fat content by proton MR spectroscopy decreased relatively by approximately one-third on tesamorelin versus a small increase on placebo, with parallel visceral fat reduction 13
Phase 2 randomized, double-blind, placebo-controlled trial of tesamorelin in adults with type 2 diabetes
—
12 months
Reductions in visceral adipose tissue and triglycerides without clinically meaningful changes in HbA1c or fasting glucose; established tolerability in a non-HIV population but did not lead to indication expansion 15
Randomized, double-blind, placebo-controlled, multicentre phase 3 trial of tesamorelin 2 mg subcutaneously daily versus placebo in adults with HIV-associated NAFLD
61
12 months
Absolute reduction in hepatic fat fraction of approximately -4.1% on tesamorelin versus +0.9% on placebo at 12 months; lower rate of fibrosis progression on tesamorelin 19
Analysis of fat quality and quantity in adults treated with tesamorelin for HIV-associated lipodystrophy
—
—
Tesamorelin improved fat quality (CT attenuation and DXA-based metrics) independent of changes in fat quantity, supporting a structural as well as quantitative effect on adipose tissue 21
Randomized trial of tesamorelin effects on neurocognitive performance in adults with HIV and abdominal obesity
—
—
Reported effects on neurocognitive performance metrics in adults with HIV and abdominal obesity; tesamorelin remains not FDA-approved for cognitive indications 25
Mechanism detail
Detailed Mechanism of Tesamorelin
Endogenous GHRH is a 44-amino-acid hypothalamic peptide secreted into hypophyseal portal blood and is the principal positive regulator of pituitary GH secretion. GHRH (1-44) is rapidly inactivated in plasma by DPP-IV cleavage of the N-terminal Tyr-Ala dipeptide, yielding GHRH (3-44) with markedly reduced potency. The trans-3-hexenoyl modification of tesamorelin's N-terminal tyrosine creates steric hindrance that protects against this cleavage, preserving GHRH-receptor agonist activity in vivo 5.
In healthy adults, Stanley and colleagues (2011) used overnight frequent venous sampling to demonstrate that tesamorelin restored pulsatile GH secretion to a pattern resembling that of younger adults, with increased mean GH concentration, increased peak amplitude, and preserved pulse frequency, accompanied by improved insulin sensitivity by frequently sampled IV glucose tolerance testing 5. Makimura and colleagues extended this analysis to show a relationship between adiponectin and endogenous GH pulse parameters in response to GHRH-analog stimulation 6. In adults with HIV-associated lipodystrophy, parallel work characterized the IGF-1 dynamics on daily tesamorelin and the relationship between IGF-1 exposure and visceral fat response 47.
Effects on liver are particularly well characterized. Stanley and colleagues (2014, JAMA) randomized 50 adults with HIV and abdominal fat accumulation plus elevated hepatic fat to tesamorelin 2 mg daily versus placebo for six months and reported a relative reduction in hepatic fat content of approximately one-third by proton magnetic resonance spectroscopy 13. The phase 3 Lancet HIV trial 19 randomized 61 adults with HIV-associated NAFLD to tesamorelin or placebo for one year, demonstrating an absolute reduction in hepatic fat fraction and a lower rate of fibrosis progression on tesamorelin. Subsequent translational work characterized tesamorelin's effects on hepatic transcriptomic signatures 20, targeted proteomic and transcriptomic responder pathways 22, and circulating markers of immune activation 22. Reductions in fibroblast growth factor 21 paralleling liver fat reduction were demonstrated by Braun and colleagues 17.
Pharmacokinetically, tesamorelin is administered subcutaneously; the published population PK analyses identify a single-compartment model with first-order absorption and a terminal half-life on the order of 26-38 minutes after subcutaneous administration in adults with HIV. Clearance is via proteolytic catabolism; cytochrome P450 enzymes are not implicated. Pulsatile endogenous GH secretion provides the durable pharmacodynamic signal that supports daily (and, in the WR formulation, weekly) dosing despite the short peptide half-life 54.
Pharmacology
Tesamorelin Pharmacokinetics & Pharmacodynamics
Pharmacokinetics
Tesamorelin is a 44-amino-acid GHRH (1-44) analog with an N-terminal trans-3-hexenoyl modification that confers resistance to DPP-IV cleavage 26. After subcutaneous administration of the 2 mg labeled dose, plasma concentrations are quantifiable within 15 minutes, with peak plasma concentrations typically reached within approximately 15-30 minutes and a terminal half-life on the order of 26-38 minutes. Despite the short peptide half-life, the pharmacodynamic effect, pulsatile endogenous GH secretion, produces a sustained downstream rise in serum IGF-1 to a new steady state typically within 2 weeks of daily dosing 54.
Population pharmacokinetic analyses in HIV-infected adults and healthy subjects [popPK studies cited in the manufactured-product labels] identified body weight as the principal covariate on apparent clearance, without clinically relevant effects of age, sex, race, renal function, or hepatic function within the studied ranges. Tesamorelin is cleared by proteolytic catabolism; cytochrome P450 enzymes are not implicated. The 2024 Egrifta WR formulation extends dosing to once weekly through a depot formulation supporting sustained subcutaneous exposure 26.
Compounded tesamorelin preparations may differ from the manufactured Egrifta SV or Egrifta WR products in lyophilization conditions, excipient profile, reconstitution diluent, and container closure; PK characteristics published for the manufactured products should not be assumed to translate without local stability and potency data 262728.
Pharmacodynamics
Pharmacodynamic effects include stimulation of pulsatile endogenous GH secretion at the pituitary somatotrope, a downstream rise in serum IGF-1 to a new steady state within approximately 2 weeks, and tissue effects mediated through the GH-IGF-1 axis including preferential lipolysis in visceral adipose tissue. With chronic dosing, body composition changes accrue over weeks to months, with measurable reductions in visceral adipose tissue by CT detectable by 13 weeks and a plateau by 26 weeks in the pivotal trials 13.
Reductions in hepatic fat by proton magnetic resonance spectroscopy are observable by 6 months in HIV-associated NAFLD 13 with continued reduction through 12 months in the phase 3 NAFLD trial 19. Fat quality measures (CT attenuation, MR-based fat composition) improve independent of fat quantity changes 21. The IGF-1 elevation is dose-dependent and is the principal labeled biomarker for monitoring.
Comparative formulations
Comparing Tesamorelin Formulations
Three FDA-approved manufactured products share the labeled indication for HIV-associated abdominal lipodystrophy: Egrifta (original 2010 daily product), Egrifta SV (2019 reformulated daily product with a four-week post-reconstitution stability window), and Egrifta WR (2024 once-weekly subcutaneous product). The drug substance is tesamorelin acetate in each. Egrifta SV simplifies patient handling relative to the original product by extending reconstituted product stability under refrigeration 26. Egrifta WR reduces injection burden from daily to weekly.
Compounded sterile lyophilized preparations vary in excipient profile, lyophilization conditions, and container closure. They are not bioequivalent to Egrifta, Egrifta SV, or Egrifta WR; clinicians should anticipate that local PK and tolerability may differ from manufactured-product published data and re-evaluate IGF-1 response and tolerability when switching 2728.
Storage
Tesamorelin Storage and Handling
Manufactured Egrifta SV lyophilized powder is stored refrigerated at 2-8 degrees C prior to reconstitution; after reconstitution with sterile water for injection, the product is stable for up to four weeks under refrigeration. Egrifta WR is stored per current labeling for the lyophilized product and reconstituted product. Patients should be instructed on cold-chain handling, reconstitution procedure, and recognition of temperature excursions warranting pharmacist consultation.
Compounded sterile injectable tesamorelin is stored per the pharmacy's stability data and beyond-use date assignment under USP General Chapter <797> 272831. Refrigerated storage is typical; the beyond-use date is shorter than the manufactured product's labeled stability unless documented stability data support an extension.
RonanRx operations
Tesamorelin Compounding & Operations
503A compounding
Compounded tesamorelin is prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies. RonanRx prepares sterile injectable preparations per USP General Chapter <797>, the official compendial standard for sterile pharmaceutical compounding, with documented active ingredient sourcing, gravimetric and analytical verification, sterility and endotoxin testing per the pharmacy's quality-management system, and full lot traceability 3132. For any nonsterile preparative steps the corresponding USP General Chapter <795> applies; the finished injectable product is governed by <797> in full.
Tesamorelin is FDA-approved as Egrifta, Egrifta SV, and Egrifta WR for HIV-associated abdominal lipodystrophy only. Per FDA's guidance on compounded drug products that are essentially copies of approved drug products 29, compounding of a 503A preparation of an FDA-approved drug is restricted unless the prescriber documents a patient-specific clinical need that the manufactured product cannot meet 30. RonanRx applies a strict review threshold for tesamorelin: compounding is restricted to documented HIV-associated lipodystrophy or a comparable medical need with a documented reason the manufactured product cannot be used (excipient sensitivity, dose individualization, or documented supply interruption). RonanRx does not compound tesamorelin for off-label use including anti-aging, general body composition in adults without HIV, or athletic performance.
Pharmacist review
Each prescription for compounded tesamorelin undergoes pharmacist review prior to dispensing. The review confirms: a documented patient-specific clinical reason that the manufactured Egrifta, Egrifta SV, or Egrifta WR product is not appropriate (excipient sensitivity, dose individualization outside the manufactured strength, documented supply interruption, or a comparable medical need); the prescribed indication falls within HIV-associated lipodystrophy or a documented clinical context with an evidence-based rationale; absence of contraindications (active malignancy, hypothalamic-pituitary axis disruption, pituitary tumor, hypersensitivity to tesamorelin or mannitol, pregnancy) 262728; documented baseline IGF-1 with a plan for periodic monitoring; documented baseline glycemic status given the labeled glucose intolerance signal; and a prescribed regimen consistent with FDA labeling unless the prescriber documents a patient-specific reason for variance.
RonanRx does not fill prescriptions for compounded tesamorelin that read as routine substitution for the manufactured products without documented clinical rationale, consistent with FDA's essentially-a-copy guidance 29. RonanRx does not compound tesamorelin for anti-aging, general body composition in adults without HIV, athletic performance, or other off-label indications outside the published efficacy program.
Quality and traceability
Active pharmaceutical ingredient is sourced from FDA-registered facilities with documented certificates of analysis. Each batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, sterility test result, endotoxin test result, and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements.
Cold chain
Compounded sterile injectable tesamorelin is a cold-chain product. Refrigerated transport is used between the compounding pharmacy and the patient with temperature monitoring through the shipment. Patients are advised to refrigerate the product on arrival, to inspect for temperature excursions, and to contact the pharmacy if cold-chain integrity is in question. Manufactured Egrifta SV and Egrifta WR follow the same refrigerated-storage convention per their labels 2728.
FAQ
Frequently Asked Questions About Tesamorelin
Is compounded tesamorelin the same as Egrifta or Egrifta WR?
Tesamorelin is FDA-approved only for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The three approved products are Egrifta (2010), Egrifta SV (2019 reformulation), and Egrifta WR (2024 once-weekly reformulation) 262728. It is not FDA-approved for weight loss, anti-aging, athletic performance, or general body composition.
How well does tesamorelin work?
In the two pivotal phase 3 trials 13 in HIV-infected adults with abdominal fat accumulation, tesamorelin 2 mg daily reduced visceral adipose tissue by approximately 15-18% at 26 weeks versus minimal change on placebo. Visceral fat re-accumulates after discontinuation. In HIV-associated NAFLD 1319, tesamorelin reduces hepatic fat content and is associated with a lower rate of fibrosis progression.
When would RonanRx compound tesamorelin?
Only when the prescriber documents a patient-specific clinical need that the manufactured Egrifta, Egrifta SV, or Egrifta WR product cannot meet, for example, sensitivity to a component of the manufactured formulation, a strength or concentration not commercially available that is medically necessary, or a documented supply interruption. RonanRx does not compound tesamorelin for off-label indications including anti-aging, body composition in adults without HIV, or athletic performance 2930.
What are the most common side effects?
Injection-site reactions, arthralgia, peripheral edema, paresthesia, hypoesthesia, myalgia, and a dose-dependent rise in IGF-1 are the most common adverse events. Hypersensitivity reactions including rare anaphylaxis have been reported 28. Glucose intolerance is a labeled concern with small increases in fasting glucose and HbA1c in some patients 1327.
Who should not take tesamorelin?
Tesamorelin is contraindicated in patients with hypothalamic-pituitary axis disruption (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, head trauma), active malignancy, hypersensitivity to tesamorelin or mannitol, and pregnancy 262728. Caution applies in diabetes mellitus and pancreatitis history.
Does tesamorelin affect cognition?
A single phase 2 trial 10 in 152 older adults (with and without mild cognitive impairment) reported improvements in executive function over 20 weeks, and a magnetic resonance spectroscopy substudy 11 documented changes in brain GABA and other metabolites. These are mechanistic findings and do not establish tesamorelin as a treatment for cognitive disorders. Tesamorelin is not FDA-approved for any cognitive indication.
Does RonanRx sell compounded tesamorelin directly to patients?
No. Compounded tesamorelin requires a patient-specific prescription written by a licensed doctor for an identified patient with a documented clinical reason that the manufactured Egrifta, Egrifta SV, or Egrifta WR product is not appropriate, plus pharmacist review before dispensing 29. RonanRx is not a direct-to-consumer storefront and does not dispense tesamorelin for off-label use 30.
Clinician resource
Download the Tesamorelin Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[falutz2007] Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV.. New England Journal of Medicine. 2007. PMID 18057338. (accessed 2026-05-11)
[falutz2008] Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.. AIDS. 2008. PMID 18690162. (accessed 2026-05-11)
[falutz2010_jaids] Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.. Journal of Acquired Immune Deficiency Syndromes. 2010. PMID 20101189. (accessed 2026-05-11)
[falutz2010_jcem] Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.. Journal of Clinical Endocrinology and Metabolism. 2010. PMID 20554713. (accessed 2026-05-11)
[stanley2011] Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.. Journal of Clinical Endocrinology and Metabolism. 2011. PMID 20943777. (accessed 2026-05-11)
[makimura2011] Makimura H, Stanley TL, Chen CY, Branch KL, Grinspoon SK. Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.. Growth Hormone and IGF Research. 2011. PMID 21531600. (accessed 2026-05-11)
[stanley2011_aids] Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.. AIDS. 2011. PMID 21516030. (accessed 2026-05-11)
[dhillon2011] Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.. Drugs. 2011. PMID 21668043. (accessed 2026-05-11)
[stanley2012] Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.. Clinical Infectious Diseases. 2012. PMID 22495074. (accessed 2026-05-11)
[baker2012] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.. Archives of Neurology. 2012. PMID 22869065. (accessed 2026-05-11)
[friedman2013] Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.. JAMA Neurology. 2013. PMID 23689947. (accessed 2026-05-11)
[jain2013] Jain S, Desai N, Bhangoo A. Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.. Reviews in Endocrine and Metabolic Disorders. 2013. PMID 23657561. (accessed 2026-05-11)
[stanley2014] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.. JAMA. 2014. PMID 25038357. (accessed 2026-05-11)
[rochira2017] Rochira V, Guaraldi G. Growth hormone deficiency and human immunodeficiency virus.. Best Practice and Research Clinical Endocrinology and Metabolism. 2017. PMID 28477736. (accessed 2026-05-11)
[clemmons2017] Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.. PLoS One. 2017. PMID 28617838. (accessed 2026-05-11)
[adrian2017] Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dube MP, Stanley T, Brown TT, Erlandson KM. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.. AIDS. 2017. PMID 28832410. (accessed 2026-05-11)
[braun2017] Braun LR, Feldpausch MN, Czerwonka N, Stanley TL, Billingsley JM, Bredella MA, Lee H, Branch K, Adler GK, Lo J, Grinspoon SK, Fitch K. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.. Growth Hormone and IGF Research. 2017. PMID 29031905. (accessed 2026-05-11)
[fourman2019] Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.. Journal of Frailty and Aging. 2019. PMID 31237318. (accessed 2026-05-11)
[stanley2019] Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.. Lancet HIV. 2019. PMID 31611038. (accessed 2026-05-11)
[fourman2020] Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Chung RT, Corey D, Stanley TL, Hadigan CM, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.. JCI Insight. 2020. PMID 32701508. (accessed 2026-05-11)
[lake2021] Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dube MP, Stanley T, Falutz J, Brown TT, Sanyal A. Tesamorelin improves fat quality independent of changes in fat quantity.. AIDS. 2021. PMID 33756511. (accessed 2026-05-11)
[stanley2021_cid] Stanley TL, Fourman LT, Wong LP, Sadreyev R, Billingsley JM, Feldpausch MN, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Branch K, Kleiner DE, Hadigan CM, Corey KE, Chung RT, Torriani M, Kellogg A, Sui SJH, Grinspoon SK. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.. Clinical Infectious Diseases. 2021. PMID 33852720. (accessed 2026-05-11)
[fourman2022] Fourman LT, Grinspoon SK. Approach to the Patient With Lipodystrophy.. Journal of Clinical Endocrinology and Metabolism. 2022. PMID 35137140. (accessed 2026-05-11)
[russo2024] Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Lu MT, Stanley TL, Fourman LT. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.. AIDS. 2024. PMID 38905488. (accessed 2026-05-11)
[ellis2025] Ellis RJ, Vaida F, Hu K, Bharti AR, Saloner R, Iudicello JE, Heaton RK, Letendre SL. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.. Journal of Infectious Diseases. 2025. PMID 39813152. (accessed 2026-05-11)
[fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
[usp_797] United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-797 (accessed 2026-05-11)
[usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)
How to access
How to Access Tesamorelin
Compounded Tesamorelin is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed Tesamorelin, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Tesamorelin.
